Abundance International Limited: Key Takeaways from AGM Shareholder Q&A

Abundance International Limited, a Singapore-incorporated company, released comprehensive responses to substantial and relevant shareholder questions ahead of its Annual General Meeting (AGM) scheduled for 21 April 2026. The responses cover recent financial performance, business strategy, and outlook, each with potential implications for investor sentiment and share price.

1. Financial Performance: Significant Losses in FY2025

• The Company reported a net loss of USD 9.16 million in FY2025, a sharp deterioration compared to the USD 276,000 net profit in FY2024. This marks the largest annual loss in the past decade.
• The losses were mainly due to a sustained downturn in chemical market prices, especially in the latter half of the year, driven by softer global demand and increased pricing pressure.
• Management implemented cost controls, procurement discipline, and tight working capital monitoring, yet these measures were insufficient against adverse external market conditions.
• The Company strategically reduced inventory to preserve cash flow, minimize exposure to price declines, and avoid further inventory write-downs. If inventory had not been disposed, projected losses would have been even higher.
• Market conditions remain uncertain, and the Company has not provided guidance on the timing of recovery. Prudent cost management and disciplined inventory control will continue to be prioritized.

2. Outlook for Chemical Business

• The return to profitability is uncertain under current market conditions. Although recent geopolitical developments have put upward pressure on chemical prices, demand recovery remains uneven.
• Sustained recovery will depend on price stability, demand, inventory levels, and broader economic factors. The Company remains cautious and cannot offer definitive guidance on profitability.

3. Diversification Efforts: Expansion Beyond China

• Revenue from China has slowed considerably, prompting the Company to accelerate expansion into overseas markets including Taiwan, Japan, and Southeast Asia.
• This diversification aims to mitigate revenue concentration risk and capitalize on supply and demand dynamics in those regions.

4. Balance Sheet and Gearing Ratio Concerns

• The Group’s gearing ratio increased to 1.38 in FY2025 from 0.95 in FY2024, primarily due to annual losses reducing the equity base, despite gains from the disposal of shares in Shanghai Sunrise Polymer Material Co., Ltd.
• As of FY2025, total assets stood at USD 71.2 million, liabilities at USD 41.8 million, and current assets exceeded current liabilities, indicating sound liquidity.
• The Company does not intend to raise additional capital through equity markets at this time. Management will continue to monitor gearing levels and manage the balance sheet prudently.

5. Strategic Developments: CypH-11 Licensing Agreement

• The Company has entered a licensing agreement for CypH-11, an agent capable of detecting viable tumour cells. Production is outsourced by the licensor, Molecular Targeting Technologies, Inc. (MTTI), to a GMP-compliant facility in the US.
• Upon regulatory approval, Abundance International intends to collaborate with established pharmaceutical partners or outsource production, leveraging external expertise and infrastructure. The Company will focus on regulatory, market development, and commercial execution in its licensed territories.

6. Capital Management and Shareholder Returns

• The Board is attentive to share price performance and is committed to delivering sustainable shareholder returns.
• Despite losses, the Company has proposed dividends for shareholder approval at the AGM, supported by gains from the Shanghai Sunrise Polymer Material disposal.
• Share buybacks may be considered in the future, subject to market conditions and financial priorities. The Board may seek a mandate from shareholders for this if appropriate.
• The Company will provide updates on the progress and commercialization of CypH-11 through its wholly-owned subsidiary, Abundance Specialty Chemicals Pte. Ltd.

7. Joint Venture Developments

• No funding was provided for the joint venture referenced in the June 2025 announcement, and following its termination, there have been no further investment discussions with former joint venture parties.

Potential Price-Sensitive Issues

• The sharp FY2025 loss and increased gearing ratio may negatively impact investor confidence and share price.
• Proposed dividends, despite losses, could be positive for shareholder returns, potentially supporting share price.
• Strategic expansion outside China and the CypH-11 commercialization may offer longer-term growth potential, but execution and regulatory risks remain.
• The possibility of future share buybacks could be supportive for the share price, depending on timing and market conditions.

Conclusion

Abundance International faces significant challenges from market conditions and financial losses, but is actively pursuing diversification, capital discipline, and new growth initiatives. Investors should monitor developments closely, especially regarding recovery in the chemical sector, expansion strategies, and the CypH-11 project, as these could materially affect share value.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult professional advisors before making investment decisions. The information is based on the Company’s official disclosures and may be subject to change.

View Abundance Intl Historical chart here